Similar results were observed when patients with CBF and NPM1-mutated AML were analyzed separately or when patients with 2022 ELN favorable AML (i.e., CBF and AML with NPM1 mutations and without FLT3-ITD mutations) were considered (Supplementary Tables 1 to 3). The gene discussed is FLT3; the disease is acute myeloid leukemia.